Cohen & Steers Global Realty Majors ETF (GRI) Stock

LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 762,236 shares of the Company's common stock, having an original exercise price of $14.30 per share, originally issued by GRI Bio in February 2024, at a reduced exercise price of $1.00 per share. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276205). The offering is expected to close on or about October 22, 2024, subject to satisfaction of customary closing conditions.

Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis

Grainger Plc (LSE:GRI) reported slower rental growth for recent months and said it expects further slowing in the coming year.  The FTSE 250-listed private landlord, which owns around 12,000 homes, said rental growth was 6.3% in the year ending 30 September 2024 on a like-for-like basis.

Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases

LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer will present at the H.C. Wainwright 26 th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.

LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for a poster presentation at the 2024 European Respiratory Congress (ERS) being held September 7-11, 2024 in Vienna, Austria.

Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and topline data on track for Q1 2025 LA JOLLA, CA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the second quarter ended June 30, 2024 and provided a corporate update. “Our focus and priority remain on the successful execution of our Phase 2a biomarker study of GRI-0621 for the treatment of IPF, with interim data by the end of the year and topline data on track for Q1 2025.

Caledonia has enhanced its sustainability reporting to align with GRI and SASB standards Caledonia has enhanced its sustainability reporting to align with GRI and SASB standards

Live video webcast on Wednesday, July 17 th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024 at 12:00 PM ET. As part of the event, Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will provide a corporate overview and business outlook.